Phase I Study of Hypofractionated Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) in the Treatment of Advanced Bladder Cancer

Trial Profile

Phase I Study of Hypofractionated Radiotherapy and Anti-PD1 Antibody (Pembrolizumab) in the Treatment of Advanced Bladder Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 17 Jun 2016

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Bladder cancer
  • Focus Adverse reactions
  • Acronyms PLUMMB
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 13 Jun 2016 Planned End Date changed from 1 Feb 2019 to 1 Jun 2019.
    • 13 Jun 2016 Planned primary completion date changed from 1 Feb 2019 to 1 Jun 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top